saccharin has been researched along with Atrial Flutter in 1 studies
Saccharin: Flavoring agent and non-nutritive sweetener.
saccharin : A 1,2-benzisothiazole having a keto-group at the 3-position and two oxo substituents at the 1-position. It is used as an artificial sweetening agent.
Atrial Flutter: Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral and intravenous flecainide is recommended for cardioversion of atrial fibrillation." | 8.12 | Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm. ( Aksoy, I; Al-Windy, N; Badings, E; Belardinelli, L; Camm, AJ; Crijns, HJGM; Elvan, A; Kowey, PR; Madhavapeddi, P; Ruskin, JN; Tuininga, YS; Van Gelder, IC, 2022) |
| "Oral and intravenous flecainide is recommended for cardioversion of atrial fibrillation." | 4.12 | Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm. ( Aksoy, I; Al-Windy, N; Badings, E; Belardinelli, L; Camm, AJ; Crijns, HJGM; Elvan, A; Kowey, PR; Madhavapeddi, P; Ruskin, JN; Tuininga, YS; Van Gelder, IC, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crijns, HJGM | 1 |
| Elvan, A | 1 |
| Al-Windy, N | 1 |
| Tuininga, YS | 1 |
| Badings, E | 1 |
| Aksoy, I | 1 |
| Van Gelder, IC | 1 |
| Madhavapeddi, P | 1 |
| Camm, AJ | 1 |
| Kowey, PR | 1 |
| Ruskin, JN | 1 |
| Belardinelli, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial Fibrillation[NCT03539302] | Phase 2 | 170 participants (Actual) | Interventional | 2018-05-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for saccharin and Atrial Flutter
| Article | Year |
|---|---|
Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Flecainide; Huma | 2022 |